Aspirin in the primary prevention of vascular disease

The Lancet

Volumn 374, Issue 9693, 2009, Pages 878-

  Cleland, John GF ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; STREPTOKINASE;

CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; LETTER; LOW DRUG DOSE; META ANALYSIS; MORTALITY; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; SYSTEMATIC REVIEW; TREATMENT DURATION; VASCULAR DISEASE;

EID: 69949086747     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61622-6     Document Type: Letter

References (5)

1. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373 (2009) 1849-1860
2. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 355 (2000) 1295-1302
3. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2 (1988) 349-360
4. ISIS-1 Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 2 (1986) 57-66
5. Dagenais G.R., Pogue J., Fox K., Simoons M.L., and Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368 (2006) 581-588